KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Staar Surgical (STAA) Cash from Financing Activities (2016 - 2026)

Staar Surgical (STAA) has disclosed Cash from Financing Activities for 17 consecutive years, with -$50000.0 as the latest value for Q1 2026.

  • For the quarter ending Q1 2026, Cash from Financing Activities rose 54.55% year-over-year to -$50000.0, compared with a TTM value of -$4.6 million through Jan 2026, down 179.58%, and an annual FY2026 reading of -$4.6 million, down 179.58% over the prior year.
  • Cash from Financing Activities was -$50000.0 for Q1 2026 at Staar Surgical, down from $983000.0 in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $7.1 million in Q3 2023 and bottomed at -$4.5 million in Q2 2025.
  • Average Cash from Financing Activities over 5 years is $1.1 million, with a median of $630500.0 recorded in 2022.
  • The sharpest move saw Cash from Financing Activities skyrocketed 398.02% in 2024, then tumbled 2885.28% in 2025.
  • Year by year, Cash from Financing Activities stood at $202000.0 in 2022, then skyrocketed by 81.68% to $367000.0 in 2023, then plummeted by 129.97% to -$110000.0 in 2024, then skyrocketed by 993.64% to $983000.0 in 2025, then plummeted by 105.09% to -$50000.0 in 2026.
  • Business Quant data shows Cash from Financing Activities for STAA at -$50000.0 in Q1 2026, $983000.0 in Q3 2025, and -$4.5 million in Q2 2025.